An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
This observational study will assess the progression-free survival, overall response and safety of Avastin (bevacizumab) in combination with chemotherapy in a real life setting in patients with metastatic colorectal cancer. Data will be collected from patients for approximately 2 years.
Colorectal Cancer
Progression-free survival in a real life setting assessed by computer tomography, Approximately 2 years
Overall response rate assessed by computer tomography, Approximately 2 years|Response of Avastin according to the sites of metastases assessed by computer tomography, Approximately 2 years|Chemotherapy regimens used in combination with Avastin, Approximately 2 years|Patient demographics eligible to receive Avastin, Approximately 2 years|Safety: incidence of adverse events, Approximately 2 years
This observational study will assess the progression-free survival, overall response and safety of Avastin (bevacizumab) in combination with chemotherapy in a real life setting in patients with metastatic colorectal cancer. Data will be collected from patients for approximately 2 years.